{"count": 16, "results": [{"_id": "34627266", "pmid": 34627266, "pmcid": "PMC8502296", "title": "Simvastatin induced ferroptosis for triple-negative breast cancer therapy", "journal": "J Nanobiotechnology", "authors": ["Yao X", "Xie R", "Cao Y", "Tang J", "Men Y", "Peng H", "Yang W"], "date": "2021-10-09T00:00:00Z", "doi": "10.1186/s12951-021-01058-1", "meta_date_publication": "2021 Oct 9", "meta_volume": "19", "meta_issue": "1", "meta_pages": "311", "score": 50286.73, "text_hl": "Herein, a novel ferroptosis nanomedicine was prepared by loading @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ (@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@SIM@@@), a ferroptosis drug, into zwitterionic @CHEMICAL_Polymers @CHEMICAL_MESH:D011108 @@@polymer@@@ coated magnetic nanoparticles (Fe3O4@PCBMA) to improve the therapeutic effect of @<m>DISEASE_Triple_Negative_Breast_Neoplasms</m> @DISEASE_MESH:D064726 @@@TNBC@@@. ", "citations": {"NLM": "Yao X, Xie R, Cao Y, Tang J, Men Y, Peng H, Yang W. Simvastatin induced ferroptosis for triple-negative breast cancer therapy J Nanobiotechnology. 2021 Oct 9;19(1):311. PMID: 34627266", "BibTeX": "@article{34627266, title={Simvastatin induced ferroptosis for triple-negative breast cancer therapy}, author={Yao X and Xie R and Cao Y and Tang J and Men Y and Peng H and Yang W}, journal={J Nanobiotechnology}, volume={19}, number={1}, pages={311}}"}}, {"_id": "40864776", "pmid": 40864776, "title": "Repurposing a Lipid-Lowering Agent to Inhibit TNBC Growth Through Cell Cycle Arrest.", "journal": "Curr Issues Mol Biol", "authors": ["Hsu YC", "Lee KT", "Pei SN", "Rau KM", "Tsai TH"], "date": "2025-08-05T00:00:00Z", "doi": "10.3390/cimb47080622", "meta_date_publication": "2025 Aug 5", "meta_volume": "47", "meta_issue": "8", "meta_pages": "", "score": 50268.652, "text_hl": "This study investigates the therapeutic potential of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ in @<m>DISEASE_Triple_Negative_Breast_Neoplasms</m> @DISEASE_MESH:D064726 @@@triple-negative breast cancer@@@ (@<m>DISEASE_Triple_Negative_Breast_Neoplasms</m> @DISEASE_MESH:D064726 @@@TNBC@@@). ", "citations": {"NLM": "Hsu YC, Lee KT, Pei SN, Rau KM, Tsai TH. Repurposing a Lipid-Lowering Agent to Inhibit TNBC Growth Through Cell Cycle Arrest. Curr Issues Mol Biol. 2025 Aug 5;47(8):. PMID: 40864776", "BibTeX": "@article{40864776, title={Repurposing a Lipid-Lowering Agent to Inhibit TNBC Growth Through Cell Cycle Arrest.}, author={Hsu YC and Lee KT and Pei SN and Rau KM and Tsai TH}, journal={Curr Issues Mol Biol}, volume={47}, number={8}}"}}, {"_id": "39233601", "pmid": 39233601, "title": "Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 x 2 factorial design, randomised controlled comparison with simvastatin.", "journal": "J Psychopharmacol", "authors": ["Chaudhry IB", "Husain MO", "Khoso AB", "Kiran T", "Husain MI", "Qurashi I", "Rahman RU", "Mehmood N", "Drake R", "Husain N", "Deakin B"], "date": "2024-09-05T00:00:00Z", "doi": "10.1177/02698811241267836", "meta_date_publication": "2024 Sep 5", "meta_volume": "", "meta_issue": "", "meta_pages": "2698811241267836", "score": 50260.543, "text_hl": "CONCLUSION: Small improvement in @<m>DISEASE_Triple_Negative_Breast_Neoplasms</m> @DISEASE_MESH:D064726 @@@negative symptoms@@@ on @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ and @CHEMICAL_Ondansetron @CHEMICAL_MESH:D017294 @@@ondansetron@@@ individually are not synergistic in combination in treating @<m>DISEASE_Triple_Negative_Breast_Neoplasms</m> @DISEASE_MESH:D064726 @@@negative symptoms@@@ of @DISEASE_Schizophrenia @DISEASE_MESH:D012559 @@@schizophrenia@@@. ", "citations": {"NLM": "Chaudhry IB, Husain MO, Khoso AB, Kiran T, Husain MI, Qurashi I, Rahman RU, Mehmood N, Drake R, Husain N, Deakin B. Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 x 2 factorial design, randomised controlled comparison with simvastatin. J Psychopharmacol. 2024 Sep 5;():2698811241267836. PMID: 39233601", "BibTeX": "@article{39233601, title={Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 x 2 factorial design, randomised controlled comparison with simvastatin.}, author={Chaudhry IB and Husain MO and Khoso AB and Kiran T and Husain MI and Qurashi I and Rahman RU and Mehmood N and Drake R and Husain N and Deakin B}, journal={J Psychopharmacol}, pages={2698811241267836}}"}}, {"_id": "40444159", "pmid": 40444159, "title": "Sodium oleate functionalized simvastatin liposomes: boosting endosomal escape and anticancer efficacy in triple negative breast cancer.", "journal": "Res Pharm Sci", "authors": ["Sadaqa E", "Satrialdi", "Kurniawan F", "Mudhakir D"], "date": "2025-03-31T00:00:00Z", "doi": "10.4103/RPS.RPS_25_24", "meta_date_publication": "2025 Apr", "meta_volume": "20", "meta_issue": "2", "meta_pages": "188-206", "score": 50246.617, "text_hl": "This study aimed to enhance @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ delivery and efficacy against @<m>DISEASE_Triple_Negative_Breast_Neoplasms</m> @DISEASE_MESH:D064726 @@@triple-negative breast cancer@@@ (TNBC) by developing liposomes modified with @CHEMICAL_osteum @CHEMICAL_MESH:C013173 @@@sodium oleate@@@ (NaOL) to improve endosomal escape. ", "citations": {"NLM": "Sadaqa E, Satrialdi, Kurniawan F, Mudhakir D. Sodium oleate functionalized simvastatin liposomes: boosting endosomal escape and anticancer efficacy in triple negative breast cancer. Res Pharm Sci. 2025 Apr;20(2):188-206. PMID: 40444159", "BibTeX": "@article{40444159, title={Sodium oleate functionalized simvastatin liposomes: boosting endosomal escape and anticancer efficacy in triple negative breast cancer.}, author={Sadaqa E and Satrialdi and Kurniawan F and Mudhakir D}, journal={Res Pharm Sci}, volume={20}, number={2}, pages={188-206}}"}}, {"_id": "23973711", "pmid": 23973711, "title": "Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.", "journal": "Biochem Biophys Res Commun", "authors": ["Park YH", "Jung HH", "Ahn JS", "Im YH"], "date": "2013-09-20T00:00:00Z", "doi": "10.1016/j.bbrc.2013.08.043", "meta_date_publication": "2013 Sep 20", "meta_volume": "439", "meta_issue": "2", "meta_pages": "275-9", "score": 50078.543, "text_hl": "@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ induces inhibition of @<m>DISEASE_Triple_Negative_Breast_Neoplasms</m> @DISEASE_MESH:D064726 @@@TNBC@@@ cells via PI3K pathway activation. ", "citations": {"NLM": "Park YH, Jung HH, Ahn JS, Im YH. Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway. Biochem Biophys Res Commun. 2013 Sep 20;439(2):275-9. PMID: 23973711", "BibTeX": "@article{23973711, title={Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.}, author={Park YH and Jung HH and Ahn JS and Im YH}, journal={Biochem Biophys Res Commun}, volume={439}, number={2}, pages={275-9}}"}}, {"_id": "27941358", "pmid": 27941358, "title": "Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial.", "journal": "Int Clin Psychopharmacol", "authors": ["Tajik-Esmaeeli S", "Moazen-Zadeh E", "Abbasi N", "Shariat SV", "Rezaei F", "Salehi B", "Akhondzadeh S"], "date": "2017-03-01T00:00:00Z", "doi": "10.1097/YIC.0000000000000159", "meta_date_publication": "2017 Mar", "meta_volume": "32", "meta_issue": "2", "meta_pages": "87-94", "score": 50064.836, "text_hl": "@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ adjunct therapy for @<m>DISEASE_Triple_Negative_Breast_Neoplasms</m> @DISEASE_MESH:D064726 @@@negative symptoms@@@ of @DISEASE_Schizophrenia @DISEASE_MESH:D012559 @@@schizophrenia@@@: a randomized double-blind placebo-controlled trial.", "citations": {"NLM": "Tajik-Esmaeeli S, Moazen-Zadeh E, Abbasi N, Shariat SV, Rezaei F, Salehi B, Akhondzadeh S. Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial. Int Clin Psychopharmacol. 2017 Mar;32(2):87-94. PMID: 27941358", "BibTeX": "@article{27941358, title={Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial.}, author={Tajik-Esmaeeli S and Moazen-Zadeh E and Abbasi N and Shariat SV and Rezaei F and Salehi B and Akhondzadeh S}, journal={Int Clin Psychopharmacol}, volume={32}, number={2}, pages={87-94}}"}}, {"_id": "26590814", "pmid": 26590814, "title": "Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.", "journal": "Breast Cancer Res Treat", "authors": ["Wolfe AR", "Debeb BG", "Lacerda L", "Larson R", "Bambhroliya A", "Huang X", "Bertucci F", "Finetti P", "Birnbaum D", "Van Laere S", "Diagaradjan P", "Ruffell B", "Trenton NJ", "Chu K", "Hittelman W", "Diehl M", "Levental I", "Ueno NT", "Woodward WA"], "date": "2015-12-01T00:00:00Z", "doi": "10.1007/s10549-015-3645-3", "meta_date_publication": "2015 Dec", "meta_volume": "154", "meta_issue": "3", "meta_pages": "495-508", "score": 50064.832, "text_hl": "@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ prevents @<m>DISEASE_Triple_Negative_Breast_Neoplasms</m> @DISEASE_MESH:D064726 @@@triple-negative breast cancer metastasis@@@ in pre-clinical models through regulation of @GENE_FOXO3 @GENE_2309 @@@FOXO3a@@@.", "citations": {"NLM": "Wolfe AR, Debeb BG, Lacerda L, Larson R, Bambhroliya A, Huang X, Bertucci F, Finetti P, Birnbaum D, Van Laere S, Diagaradjan P, Ruffell B, Trenton NJ, Chu K, Hittelman W, Diehl M, Levental I, Ueno NT, Woodward WA. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Res Treat. 2015 Dec;154(3):495-508. PMID: 26590814", "BibTeX": "@article{26590814, title={Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.}, author={Wolfe AR and Debeb BG and Lacerda L and Larson R and Bambhroliya A and Huang X and Bertucci F and Finetti P and Birnbaum D and Van Laere S and Diagaradjan P and Ruffell B and Trenton NJ and Chu K and Hittelman W and Diehl M and Levental I and Ueno NT and Woodward WA}, journal={Breast Cancer Res Treat}, volume={154}, number={3}, pages={495-508}}"}}, {"_id": "31400433", "pmid": 31400433, "title": "EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers.", "journal": "Int J Pharm", "authors": ["Matusewicz L", "Filip-Psurska B", "Psurski M", "Tabaczar S", "Podkalicka J", "Wietrzyk J", "Ziółkowski P", "Czogalla A", "Sikorski AF"], "date": "2019-10-05T00:00:00Z", "doi": "10.1016/j.ijpharm.2019.118605", "meta_date_publication": "2019 Oct 5", "meta_volume": "569", "meta_issue": "", "meta_pages": "118605", "score": 50061.445, "text_hl": "@GENE_EGFR @GENE_1956 @@@EGFR@@@-targeted immunoliposomes as a selective delivery system of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@, with potential use in treatment of @<m>DISEASE_Triple_Negative_Breast_Neoplasms</m> @DISEASE_MESH:D064726 @@@triple-negative breast cancers@@@.", "citations": {"NLM": "Matusewicz L, Filip-Psurska B, Psurski M, Tabaczar S, Podkalicka J, Wietrzyk J, Ziółkowski P, Czogalla A, Sikorski AF. EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers. Int J Pharm. 2019 Oct 5;569():118605. PMID: 31400433", "BibTeX": "@article{31400433, title={EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers.}, author={Matusewicz L and Filip-Psurska B and Psurski M and Tabaczar S and Podkalicka J and Wietrzyk J and Ziółkowski P and Czogalla A and Sikorski AF}, journal={Int J Pharm}, volume={569}, pages={118605}}"}}, {"_id": "28826913", "pmid": 28826913, "title": "Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation.", "journal": "Eur J Pharmacol", "authors": ["Kou X", "Yang Y", "Jiang X", "Liu H", "Sun F", "Wang X", "Liu L", "Liu H", "Lin Z", "Jiang L"], "date": "2017-10-15T00:00:00Z", "doi": "10.1016/j.ejphar.2017.08.022", "meta_date_publication": "2017 Oct 15", "meta_volume": "813", "meta_issue": "", "meta_pages": "161-171", "score": 50061.273, "text_hl": "@CHEMICAL_Vorinostat @CHEMICAL_MESH:D000077337 @@@Vorinostat@@@ and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ have synergistic effects on @<m>DISEASE_Triple_Negative_Breast_Neoplasms</m> @DISEASE_MESH:D064726 @@@triple-negative breast cancer@@@ cells via abrogating @GENE_RAB7B @GENE_338382 @@@Rab7@@@ prenylation.", "citations": {"NLM": "Kou X, Yang Y, Jiang X, Liu H, Sun F, Wang X, Liu L, Liu H, Lin Z, Jiang L. Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation. Eur J Pharmacol. 2017 Oct 15;813():161-171. PMID: 28826913", "BibTeX": "@article{28826913, title={Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation.}, author={Kou X and Yang Y and Jiang X and Liu H and Sun F and Wang X and Liu L and Liu H and Lin Z and Jiang L}, journal={Eur J Pharmacol}, volume={813}, pages={161-171}}"}}, {"_id": "27765921", "pmid": 27765921, "pmcid": "PMC5352107", "title": "Triple-negative breast cancer: is there a treatment on the horizon?", "journal": "Oncotarget", "authors": ["Yao H", "He G", "Yan S", "Chen C", "Song L", "Rosol TJ", "Deng X"], "date": "2017-01-03T00:00:00Z", "doi": "10.18632/oncotarget.12284", "meta_date_publication": "2017 Jan 3", "meta_volume": "8", "meta_issue": "1", "meta_pages": "1913-1924", "score": 50060.902, "text_hl": "The @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@-lowering statins (@GENE_HMGCR @GENE_3156 @@@3-hydroxy-3-methyl-glutaryl coenzyme A reductase@@@ inhibitors), including @CHEMICAL_Lovastatin @CHEMICAL_MESH:D008148 @@@lovastatin@@@ and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@, have been shown to preferentially target @<m>DISEASE_Triple_Negative_Breast_Neoplasms</m> @DISEASE_MESH:D064726 @@@TNBC@@@ compared with non-@<m>DISEASE_Triple_Negative_Breast_Neoplasms</m> @DISEASE_MESH:D064726 @@@TNBC@@@. ", "citations": {"NLM": "Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017 Jan 3;8(1):1913-1924. PMID: 27765921", "BibTeX": "@article{27765921, title={Triple-negative breast cancer: is there a treatment on the horizon?}, author={Yao H and He G and Yan S and Chen C and Song L and Rosol TJ and Deng X}, journal={Oncotarget}, volume={8}, number={1}, pages={1913-1924}}"}}]}